Kyle Bass files IPR against patent related to Imbruvica (Ibrutinib)
After Bass' petition was filed Monday, Pharmacyclics shares dropped. Not by a huge amount, as Acorda's did after the Ampyra challenge. But plenty to deliver a significantly bigger profit--provided you were short enough.
Ibrutinib was first designed and synthesized at Celera Genomics .
Approved by the FDA for treatment of mantle cell lymphoma, it is being studied for use against other afflictions, including diffuse large B-cell lymphoma and multiple myeloma.